New York State Common Retirement Fund increased its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 9.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 286,453 shares of the biotechnology company’s stock after buying an additional 24,715 shares during the quarter. New York State Common Retirement Fund owned about 0.39% of Momenta Pharmaceuticals worth $4,841,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Thrivent Financial For Lutherans lifted its position in Momenta Pharmaceuticals by 10.7% during the second quarter. Thrivent Financial For Lutherans now owns 40,540 shares of the biotechnology company’s stock worth $685,000 after buying an additional 3,920 shares during the period. PNC Financial Services Group Inc. lifted its position in Momenta Pharmaceuticals by 0.4% during the second quarter. PNC Financial Services Group Inc. now owns 76,863 shares of the biotechnology company’s stock worth $1,299,000 after buying an additional 303 shares during the period. Profund Advisors LLC lifted its position in Momenta Pharmaceuticals by 13.1% during the second quarter. Profund Advisors LLC now owns 13,172 shares of the biotechnology company’s stock worth $223,000 after buying an additional 1,530 shares during the period. Edmond DE Rothschild Holding S.A. lifted its position in Momenta Pharmaceuticals by 4.8% during the second quarter. Edmond DE Rothschild Holding S.A. now owns 440,000 shares of the biotechnology company’s stock worth $7,436,000 after buying an additional 20,000 shares during the period. Finally, BlackRock Inc. lifted its position in Momenta Pharmaceuticals by 7.1% during the second quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock worth $158,868,000 after buying an additional 626,415 shares during the period. Hedge funds and other institutional investors own 93.88% of the company’s stock.

In other news, President Craig A. Wheeler sold 35,667 shares of Momenta Pharmaceuticals stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $19.03, for a total value of $678,743.01. Following the transaction, the president now directly owns 286,121 shares in the company, valued at $5,444,882.63. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock in a transaction dated Monday, August 21st. The stock was sold at an average price of $15.07, for a total value of $62,028.12. Following the completion of the transaction, the president now owns 269,231 shares in the company, valued at $4,057,311.17. The disclosure for this sale can be found here. Insiders sold 79,663 shares of company stock valued at $1,414,498 in the last ninety days. Insiders own 4.40% of the company’s stock.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ MNTA) opened at 13.60 on Tuesday. The firm’s market cap is $1.01 billion. The stock has a 50 day moving average price of $16.30 and a 200-day moving average price of $15.80. Momenta Pharmaceuticals, Inc. has a 1-year low of $10.75 and a 1-year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.50). Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The company had revenue of $23.57 million during the quarter, compared to analysts’ expectations of $24.64 million. During the same quarter in the previous year, the firm earned ($0.31) earnings per share. The business’s quarterly revenue was down 10.8% compared to the same quarter last year. On average, equities research analysts expect that Momenta Pharmaceuticals, Inc. will post ($1.50) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2017/10/17/momenta-pharmaceuticals-inc-mnta-position-boosted-by-new-york-state-common-retirement-fund.html.

Several equities analysts recently weighed in on the company. ValuEngine downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. BidaskClub downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Maxim Group set a $6.00 target price on Momenta Pharmaceuticals and gave the stock a “sell” rating in a research report on Thursday, August 3rd. Zacks Investment Research downgraded Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 4th. Finally, J P Morgan Chase & Co restated a “hold” rating and set a $14.00 price target on shares of Momenta Pharmaceuticals in a research note on Thursday, October 5th. Three equities research analysts have rated the stock with a sell rating and nine have issued a hold rating to the company. Momenta Pharmaceuticals has an average rating of “Hold” and an average target price of $15.00.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.